MPN Treatment Methods with Therapeutic Compounds
Summary
USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.
What changed
USPTO published a patent application (US20260097028A1) for therapeutic methods and pharmaceutical compositions treating myeloproliferative neoplasms. The application claims combination therapies pairing novel compounds (Formula I/II) with established agents including JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, interferons, or nucleoside analogs for treating PV, ET, and myelofibrosis.
Pharmaceutical companies and researchers developing MPN treatments should monitor this application as it may affect freedom-to-operate considerations for combination therapies in this space. Patent prosecution may lead to granted claims covering these therapeutic combinations.
What to do next
- Monitor for updates on patent application status
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of Treating Myeloproliferative Neoplasms
Application US20260097028A1 Kind: A1 Apr 09, 2026
Inventors
Wayne Rothbaum
Abstract
Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.
CPC Classifications
A61K 31/451 A61K 9/0019 A61K 31/706 A61K 38/212 A61K 45/06 A61P 35/02
Filing Date
2025-02-18
Application No.
19055807
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.